The use of placebos in phase III clinical trials in Brazil

Gustavo Butzge Rubenich; Stephanie Tomasi Heck; Fernando Hellmann; Bruno Rodolfo Schlemper Junior

doi:10.18294/sc.2015.418

The use of placebos in phase III clinical trials in Brazil

Gustavo Butzge Rubenich Medicine Student, Universidade do Oeste de Santa Catarina, Brazil. , Stephanie Tomasi Heck Medicine Student, Universidade do Oeste de Santa Catarina, Brazil. , Fernando Hellmann Naturologist. Master Degree in Public Health. Professor, Universidade do Sul de Santa Catarina, Brazil. , Bruno Rodolfo Schlemper Junior Physician. Doctor in Medicine. Professor, Universidade do Oeste de Santa Catarina, Brazil.

Published: 4 March 2015

https://doi.org/10.18294/sc.2015.418

Abstract views

639

Metrics Loading ...

PDF

PDF (Español)

Abstract

In 2008, Brazil’s Federal Council of Medicine [Conselho Federal de Medicina] (CFM) – regulatory and supervisory agency on the ethical practice of medicine – banned the participation of Brazilian doctors in studies using placebos for diseases with efficient and effective treatment. This position differs with the Helsinki Declaration, which allows the use of placebos in methodologically justified conditions. To ascertain whether the CMF’s ethical regulation modified the use of placebos in phase III clinical trials in Brazil, characteristics of the records in ClinicalTrials.govwere researched in the periods from 2003 to 2007 and from 2009 to 2013. The conclusions reached were: a) the regulations issued by the CFM in 2008 were ineffective and the position adopted by the Helsinki Declaration prevails; b) there was significant sponsorship by the multinational pharmaceutical industry of trials with placebos; c) the research was predominantly on new drugs for chronic diseases, with little study done of the neglected diseases which are of great importance to Brazil.

Keywords: Ethics, Research, Medical, Clinical Trial, Placebos, Helsinki Declaration

References

1. Beecher HK. The powerful placebo. JAMA. 1955;159(17):1602-1606.

2. Shapiro AK. A contribution to a history of the placebo effect. Systems Research and Behavioral Science. 1960;5(2):109-135.

3. Marcus DM. Clinical and ethical aspects of placebos in clinical practice. JAMA Internal Medicine. 2013;173(8):711-712.

4. Pignarre P. O que é o medicamento?: Um objeto estranho entre ciência, mercado e sociedade. São Paulo: Editora 34; 1999.

5. Lederer SE. Subjected to science: human experimentation in America before the Second World War. Baltimore: Johns Hopkins University Press; 1995.

6. Human D, Fluss SS. The World Medical Association’s Declaration of Helsinki: Historical and contemporary perspectives [Internet]. 2001 [cited18 Set 2014]. Available from: http://www.wma.net/en/20activities/10ethics/10helsinki/draft_historical_contemporary_perspectives.pdf.

7. Bok S. The ethics of giving placebos. Scientific American. 1974;231(5):17-23.

8. Angell M. Ethical imperialism?: Ethics in international collaborative clinical research. New England Journal of Medicine. 1988;319(16):1081-1083.

9. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. New England Journal of Medicine. 1994;331(6):394-398.

10. Malik AY, Ghafoor F. International collaborative trials, placebo controls and the Declaration of Helsinki: need for clarification in paragraph 32. Indian Journal of Medical Ethics. 2012;9(1):13-17.

11. Schlemper Junior BR. Historia del control ético de la investigación en seres humanos en Brasil. Boletín Fármacos [Internet]. 2008;11(5):9-10 [cited 20 Aug 2014). Available from: http://www.saludyfarmacos.org/wp-content/files//nov08.pdf.

12. Schlemper Junior BR, Hellmann F. Controvérsias em tempos de mudanças na Declaração de Helsinque e a experiência brasileira em Ética em Pesquisa. In: Caponi S, Verdi M, Brzozowski FS, Hellmann F, organizadores. Medicalização da vida: ética, saúde pública e indústria farmacêutica. 2a ed. Curitiba: Editora Prismas; 2013.

13. Associação Médica Mundial (AMM). Declaração de Helsinki VI [Internet]. [cited 12 Mar 2014]. Available from: http://www.wma.net/es/30publications/10policies/b3/17c_es.pdf.

14. Garrafa V, Lorenzo C. Helsinque 2008: redução de proteção e maximização de interesses privados. Revista da Associação Médica Brasileira. 2009;55(5):497-520.

15. Conselho Federal de Medicina (CFM). Resolução Nº 1885, de 23 de outubro de 2008 [Internet]. 2008 [cited 20 Aug 2014]. Available from: http://www.portalmedico.org.br/resolucoes/CFM/2008/1885_2008.htm.

16. Brasil, Ministério da Saúde, Conselho Nacional de Saúde (CNS). Resolução Nº 404, de 1º de agosto de 2008 [Internet]. 2008 [cited 25 Aug 2014]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/cns/2008/res0404_01_08_2008.html.

17. Conselho Federal de Medicina. Resolução Nº 1931, de 17 de setembro de 2009 [Internet]. 2009 [cited 20 Mar 2014]. Available from: http://www.portalmedico.org.br/resolucoes/CFM/2009/1931_2009.pdf.

18. National Institutes of Health. About this site [Internet]. 2014 [cited 25 Aug 2014]. Available from: https://www.clinicaltrials.gov/ct2/about-site.

19. De Angelis C, Drazen JM, Frizelle FA, Haug C, et al. Is this clinical trial fully registered? — A statement from the International Committee of Medical Journal Editors. New England Journal of Medicine. 2005;352(23):2436-2438.

20. International Committee of Medical Journal Editors (ICMJE). Update on trials registration [Internet]. 2004 [cited 15 Oct 2014]. Available from: http://www.icmje.org/news-and-editorials/trial_reg_oct2004.html.

21. Laine C, Horton R, DeAngelis CD, Godlee F, et al. Update on Trials Registration: Clinical Trial Registration: Looking Back and Moving Ahead [Internet]. International Committee of Medical Journal Editors (ICMJE); 2007 [cited 27 Sep 2014]. Available from: http://www.icmje.org/news-and-editorials/clincial_trial_reg_jun2007.html.

22. Scariot M, Pereira M. Ensaios clínicos aprovados pela Agência Nacional de Vigilância Sanitária. Brasília Médica [Internet]. 2011;48(3) [cited 9 Sep 2014]. Available from: http://www.ambr.org.br/ensaios-clinicos-aprovados-pela-agencia-nacional-de-vigilancia-sanitaria/.

23. National Institutes of Health. Map of all studies in ClinicalTrials.gov [Internet]. 2014 [cited 20 Sep 2014]. Available from: https://clinicaltrials.gov/ct2/search/map.

24. Gomes RP, Pimentel VP, Landim AB, Pieroni JP. Ensaios clínicos no Brasil: competitividade internacional e desafios. BNDES Setorial Complexo Industrial da Saúde [Internet]. 2012 [cited 9 Set 2014];36:45-84. Available from: http://www.bndes.gov.br/SiteBNDES/export/sites/default/bndes_pt/Galerias/Arquivos/conhecimento/bnset/set3602.pdf.

25. Zucchetti C, Morrone FB. Perfil da pesquisa clínica no Brasil. Revista do Hospital das Clínicas de Porto Alegre. 2012;32(3):340-347.

26. Shah S. Cazadores de cuerpos: la experimentación farmacéutica con los pobres del mundo. Madrid: 451 Editores; 2009.

27. Petryna A. When experiments travel: Clinical trials and the global search for human subjects. Princeton: Princeton University Press; 2009.

28. Petryna A. Experimentalidade: Ciência, capital e poder no mundo dos ensaios clínicos. Horizontes Antropológicos. 2011;17(35):127-160.

29. Associação da Indústria Farmacêutica de Pesquisa (Interfarma). Guia Interfarma [Internet]. 2014 [cited 16 Sep 2014]. Available from: http://www.interfarma.org.br/biblioteca.php? publicacao=&categoria=G.

30. Bodenheimer T. Uneasy alliance: Clinical investigators and the pharmaceutical industry. New England Journal of Medicine. 2000;342(20):1539-1544.

31. Freitas CBD, Schlemper Junior BR. Progress and challenges of clinical research with new medications in Brazil. In: Homedes N, Ugalde A, organizadores. Clinical trials in Latin America: Where ethics and business clash. London: Springer; 2014.

32. Statista. 2014 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) [Internet]. 2014 [cited 18 Sep 2014]. Available from: http://www.statista.com/statistics/272717/top-global-biotech-and-pharmaceutical-companies-based-on-revenue/.

33. Zucchetti C, Morrone FB. Perfil da pesquisa clínica no Brasil. Revista do Hospital das Clínicas de Porto Alegre. 2012;32(3):340-347.

34. Sousa MSA, Franco MAG, Massud Filho J. A nova declaração de Helsinque e o uso de placebo em estudos clínicos no Brasil: a polêmica continua. Revista Médica (São Paulo). 2012;91(3):178-188.

35. Quental C, Salles Filho S. Ensaios clínicos: capacitação nacional para avaliação de medicamentos e vacinas. Revista Brasileira de Epidemiologia. 2006;9(4):408-424.

36. Zago MA. A pesquisa clínica no Brasil. Ciência & Saúde Coletiva. 2004;9(2):363-374.

37. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. The Lancet. 2002;359(9324):2188-2194.

38. Moreno RP. La investigación de la industria farmacéutica: ¿condicionada por los intereses del mercado? Acta Bioethica. 2011;17(2):237-246.

39. Ugalde A, Homedes N. Four words regarding clinical trials: science/profit, risks/benefits. Salud Colectiva. 2011;17(2):135-148.

40. Spellberg B, Martin B, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN. Combating antimicrobial resistance: policy recommendations to save lives. Clinical Infectious Disease. 2011;52(Suppl 5):S397-S428.

41. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine. 2000;133(6):455-463.

42. Miller FG, Brod H. What makes placebo-controlled trials unethical? The American Journal of Bioethics. 2002;2(2):3-9.

43. Katz KA, Karlawish JH, Chiang DS, Bognet RA, Propert KJ, Margolis DJ. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: A cross-sectional study. Jounal of the American Academy of Dermatology. 2006;5(5):814-822.

44. Scott D, Halpern BS, Jason HT, Karlawish MD. Placebo-controlled trials are unethical in clinical hypertension research. Archives of Internal Medicine. 2000; 160(20):3167-3168.

45. Jordão CE, Mêdola PR, Luciane LC, Rosalen PL. Uso de placebo em experimentos clínicos envolvendo seres humanos no Brasil. Revista de Direito Sanitário. 2008;9(2):31-46.

46. Kottow M. De Helsinki a Fortaleza: una Declaración desangrada. Revista Bioética. 2014;22(1):28-33.

47. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. New England Journal of Medicine. 1997;337(12):853-856.

48. Angell M. The ethics of clinical research in the Third World. [Editorials]. New England Journal of Medicine. 1997;337(12):847-849.

49. Macklin R. Double standard in multinational research. In: Porto D, Schlemper Junior BR, Martins GZ, Dutra T, Hellmann F. Bioética: saúde, pesquisa, educação. Brasília: CFM, SBB; 2014.

50. Mayor S. Half of drug trials with results on ClinicalTrials.gov are not published in journals. BMJ. 2013;347:f7219.

51. Kottow M. El uso de placebos en estudios clínicos y comunitarios: consideraciones éticas. Cuadernos Médico Sociales (Chile). 2009;4(2):94-100.

52. Cabral MML, Schindler HC, Abath FGC. Regulamentações, conflitos e ética da pesquisa médica em países em desenvolvimento. Revista de Saúde Pública. 2006;40(3):521-527.

53. Verástegui Avilés E, Valdez-Martínez E. Regulación y ética de los ensayos clínicos en México. In: Homedes N, Ugalde A, coordinadores. Ética y ensayos clínicos en América Latina. Buenos Aires: Lugar Editorial; 2012.

54. Beauchamp TL, Childress JF. Princípios de ética biomédica. São Paulo: Edições Loyola; 2002.

55. Brasil, Ministério da Saúde, Conselho Nacional de Saúde. Resolução CNS Nº 466, de 12 de dezembro de 2012 [Internet]. 2012 [cited 10 Sep 2014]. Available from: http://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf.

56. Sociedade Brasileira de Bioética. Moção a respeito da Declaração de Helsinque, de 26 de setembro de 2013 [Internet]. 2013 [cited 10 Sep 2014]. Available from: http://www.sbbioetica.org.br/noticia/mocao-da-sbb-a-respeito-da-revisao-da-declaracao-de-helsinque-2013/.

57. Confederación Médica Latinoamericana y del Caribe (CONFEMEL). [Internet]. 2014 [cited 18 Jul 2014]. Available from: www.confemel.com/.

58. Confederación Médica Latinoamericana y del Caribe (CONFEMEL). Declaración de Bogotá sobre investigación médica en seres humanos [Internet]. 2012 [cited 18 Jul 2014]. Available from: http://www.confemel.com/asambleas/xvaao/declaracion_bogota.pdf.

59. Confederación Médica Latinoamericana y del Caribe (CONFEMEL). Declaración de Pachuca 2013 [Internet]. 2013 [cited 18 Jun 2014]. Available from: http://www.confemel.com/asambleas/xviaao/declaracion_helsinki.pdf.

60. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA. 2012;307(17):1838-1847.

61. Zarin DA, Tse T, Ide NC. Trial registration at ClinicalTrials.gov between May and October 2005. New England Journal of Medicine. 2005;353(26):2779-2787.

62. Viergever RF, Ghersi D. The quality of registration of clinical trials. Plos ONE. 2011;6(2):1-8.

63. Homedes N, Ugalde A. La globalización de la investigación clínica en América Latina. In: Homedes N, Ugalde A, coordinadores. Ética y ensayos clínicos en América Latina. Buenos Aires: Lugar Editorial; 2012.